Dupixent® (dupilumab) Becomes First Biologic Approved in China for COPD Treatment – A Major Milestone for Regeneron Pharmaceuticals
Sep 28, 2024
Copd Stock Market Invest
Dupixent® (dupilumab) Becomes First Targeted Therapy in EU for COPD Patients with Elevated Eosinophils
Jul 3, 2024
FDA Prioritizes Review of Dupixent for COPD with Type 2 Inflammation, a Potential Breakthrough by Regeneron and Sanofi
Jun 1, 2024